

# Raul Mostoslavsky, MD, PhD



## Mostoslavsky Laboratory

Ruben Boon, PhD  
Hyo-Min Cho, PhD  
Jee-Eun Choi, PhD  
Thomas Clarke, PhD  
Christina Ferrer, PhD  
Yuchao Gu, PhD\*\*  
Yasmin Hernandez Barco, MD  
Sam Linder\*  
Raul Mostoslavsky, MD, PhD  
Lara Roach\*  
Giorgia Silveira, PhD  
Nicole Smith, BSc  
Jordan Todd\*

\* Graduate student

\*\* Visiting Professor, The Ocean University of China


Research in **the Mostoslavsky laboratory** focuses on the crosstalk between chromatin dynamics and cellular metabolism. In particular, we have focused on sirtuins, a family of proteins first discovered in yeast that plays a critical role in many human diseases, including cancer. The yeast protein Sir2 enables yeast cells to survive under conditions of nutrient stress and functions as a modulator of lifespan. While recent studies indicate that some of the mammalian sirtuin (SIRT) homologues also play a role in stress resistance and metabolic homeostasis, their precise molecular functions remain unclear. Most of our work involves the Sir2 mammalian homolog known as SIRT6. Our research indicates that SIRT6 modulates glucose metabolism and DNA repair and functions as a strong tumor suppressor gene. Using transgenic mouse models and other experimental systems, we are exploring the role of SIRT6 and metabolism in tumorigenesis and other disease processes, as well as trying to understand the crosstalk between metabolism and epigenetics.

The DNA and the histones are arranged in the nucleus in a highly condensed structure known as chromatin. Cellular processes that unwind the double helix—such as transcription, replication and DNA repair—have to overcome this natural barrier to DNA accessibility.

Multicellular organisms also need to control their use of cellular energy stores. Glucose metabolism plays a crucial role in organismal homeostasis, influencing energy consumption, cell proliferation, stress resistance and lifespan. Defective glucose utilization causes numerous diseases ranging from diabetes to an increased tendency to develop tumors. For cells to respond appropriately to changes in energy status, they need a finely tuned system to modulate chromatin dynamics in order to respond to metabolic cues. Reciprocally, chromatin changes necessary for cellular functions need as well to be coupled to metabolic adaptations.

Our lab is interested in understanding the influence of chromatin on nuclear processes (gene transcription, DNA recombination and

DNA repair) and the relationship between chromatin dynamics and the metabolic adaptation of cells. One of our interests includes the study of a group of proteins called SIRT6s, the mammalian homologues of the yeast Sir2. Sir2 is a chromatin silencer that functions as an NAD-dependent histone deacetylase to inhibit DNA transcription and recombination. In the past few years, we have been exploring the crosstalk between epigenetics and metabolism. In particular, our work has focused on the mammalian Sir2 homologue, SIRT6. In recent years, we have identified SIRT6 as a key modulator of metabolism. Mice lacking SIRT6 exhibit severe metabolic defects, including hypoglycemia and hypoinsulinemia. SIRT6 appears to modulate glucose flux inside the cells, functioning as a histone H3K9 deacetylase to silence glycolytic genes acting as a coexpressor of Hif1alpha, in this way directing glucose away from the TCA cycle to reduce intracellular ROS levels. This function appears critical for glucose homeostasis, as SIRT6 deficient animals die early in life from hypoglycemia. Remarkably,



*SIRT6: A Chromatin Modulator of Glucose Homeostasis.*

SIRT6 acts as a tumor suppressor in colon cancer, regulating cancer metabolism through mechanisms that by-pass known oncogenic pathways. Cancer cells prefer fermentation (i.e., lactate production) to respiration. Despite being described by biochemist and Nobel laureate Otto Warburg decades ago (i.e., the Warburg effect), the molecular mechanisms behind this metabolic switch remain a mystery. We believe SIRT6 may function as a critical modulator of the Warburg effect, providing a long-sought molecular explanation to this phenomenon. We have also uncovered key roles for SIRT6 in DNA repair (anchoring the chromatin remodeler SNF2H to DNA breaks) and early development (acting as a repressor of pluripotent genes), indicating broad biological functions for this chromatin deacetylase. More recently, we identified SIRT6 as a robust tumor suppressor in pancreatic cancer, where it silences the oncofetal protein Lin28b, protecting against aggressive tumor phenotypes. As such, SIRT6 represents an example of a chromatin factor modulated by cancer cells to acquire “epigenetic plasticity”.

Our current studies are directed at determining how the DNA repair and metabolic functions of SIRT6 may be related to each other. We are exploring novel metabolic liabilities in cancer, as well as broader chromatin roles in DNA repair. We use a number of experimental systems, including biochemical and biological approaches, as well as genetically engineered mouse models.

#### Projects:

1. Deciphering how SIRT6 regulates chromatin structure
2. Determining the role of SIRT6 in tumorigenesis using mouse models
3. Elucidating the role of histone modifications and chromatin dynamics in DNA repair
4. Determining molecular crosstalk between epigenetics and metabolism
5. Assessing metabolic liabilities in cancer and metastases

#### Selected Publications:

Etchegaray J-P, Zhong L, Li C, Henriques T, Ablondi E, Nakadai T, Van Rechem C, Ferrer, C, Ross KN, Choi J-E, Samarakkody A, Ji F, Chang A, Sadreyev RI, Ramaswamy S, Nechaev S, Whetstine JR, Roeder RG, Adelman K, Goren A, and Mostoslavsky R. (2019). The histone deacetylase SIRT6 restrains transcription elongation via promoter-proximal pausing. *Molecular Cell*. 2019 Jul 20. pii: S1097-2765(19)30491-5.

Ferrer C, Alders M, Postma AV, Park S, Klein MA, Cetinbas M, Pajkrt E, Glas A, van Koningsbruggen S, Christofels VM, Mannens MMAM, Knelt L, Etchegaray JP, Sadreyev R, Denu JM, Mostoslavsky G, van Maarle MC, and Mostoslavsky, R. (2018). An inactivating mutation in the histone deacetylase SIRT6 causes human perinatal lethality. *Genes Dev*. 2018 Mar 1;32(5-6):373-388.

Kugel S, Sebastian C, Fitamant J, Ross KN, Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, Ramaswamy S, Sadreyev RI, Goren A, Deshpande V, Bardeesy N, and Mostoslavsky R. (2016). SIRT6 suppresses pancreatic cancer through control of Lin28b. *Cell*. 2016 Jun 2;165(6):1401-15.

Toiber D, Erdel F, Bouazoune K, Silberman DM, Zhong L, Mulligan P, Sebastian C, Cosentino C, Martinez-Pastor B, Giacosa S, D'Urso A, Naar AM, Kingston R, Rippe K, and Mostoslavsky R. SIRT6 recruits SNF2H to DNA break sites, preventing genomic instability through chromatin remodeling. *Molecular Cell*. 2013 Aug 22;51(4):454-68.

Sebastian C, Zwaans BM, Silberman DM, Gymrek MA, Goren A, Zhong L, Ran O, Truelove J, Guimaraes AR, Toiber D, Cosentino C, Greenon JK, MacDonald AI, McGlynn L, Maxwell F, Edwards J, Giacosa S, Guccione E, Weisleder R, Bernstein BE, Regev A, Shiels PG, Lombard DB and Mostoslavsky R. The Histone Deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. *Cell*. 2012 Dec 7;151(6):1185-99.